Increased skin autofluorescence of children and adolescents with type 1 diabetes despite a well-controlled HbA1c: results from a cohort study. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: van der Heyden, Josine; Birnie, Erwin; Mul, Dick; Bovenberg, Sarah; Veeze, Henk; Aanstoot, Henk-Jan
• Is Part Of: BMC endocrine disorders. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 8
• Publication Date: 2016-12
• Subjects: Pediatrics -- Type 1 diabetes -- Skin autofluorescence -- Skin advanced glycation end products -- Diabetic complications; Endocrine glands -- Diseases -- Periodicals; 616.4005
• DOI: 10.1186/s12902-016-0129-3
• Languages: English
• ISSNs: 1472-6823

Abstract

Abstract Background Early identification of children and adolescents with type 1 diabetes at high risk for development of complications is important, as early intervention may prevent further deterioration. Here we investigate the applicability of assessing skin advanced glycation end products (sAGEs) by skin autofluorescence (SAF) as a potential surrogate risk marker. Methods This study included a cross-sectional analysis of SAF in 77 patients with type 1 diabetes mellitus and 118 healthy controls across age categories (11–12, 13–14, 15–16, and 17–19 years old). In patients, the impact of current and historical glycated hemoglobin (HbA1c) values, age, and duration of diabetes on SAF was studied in a retrospective cohort study and analyzed with multivariable analyses. Results SAF was significantly and similarly higher in patients when compared with controls across all age categories (P ≤0.009). For patients, age, duration of diabetes, and current and historical HbA1c were associated with SAF in univariate analysis. Multivariate analysis showed no association between HbA1c and SAF. A subgroup of patients with a HbA1c-within-target (≤7.5 %/59 mmol/mol) were observed to have high SAF. Conclusion Children and adolescents with type 1 diabetes show higher SAF than controls. The presumed correlation of high HbA1c with high SAF does not exist in all patients. Thus, use of this non-invasive measure may provide a surrogate marker for diabetic complications, additional to HbA1c.